Winter 2014 – Vemurafenib: Background, Patterns of Resistance, and Strategies to Combat Resistance in Melanoma

Vemurafenib: Background, Patterns of Resistance, and Strategies to Combat Resistance in Melanoma.
 
Arjun Dupati* and Liza Gill
 
Author Affiliations:
College of Human Medicine, Michigan State University, East Lansing, MI, USA

 

 
Full Text Article PDF

 
 
*Corresponding author: Arjun Dupati; dupatiar[at]gmail.com
Arjun Dupati and Liza Gill contributed equally to the production of this manuscript.
 
Key Words: Vemurafenib; Molecular Targeted Therapy; Melanoma Drug Resistance; Metastatic Melanoma; Tyrosine Kinase Inhibitor; Melanoma Treatment.
 
Abstract:
Introduction: Finding an effective treatment for metastatic melanoma has posed a series of challenges. Vemurafenib, a B-RAF tyrosine kinase inhibitor, has been one of the most successful medications to date in the treatment of metastatic melanoma. B-RAF is a serine/threonine kinase that is a part of the RAS-RAF-MEK-ERK signal transduction pathway, which plays a pivotal role in cellular proliferation, differentiation, and survival. Mutations in the B-RAF protein lead to a deregulated activation of MAPK and ERK.
The focus of this review article is resulting resistance to vemurafenib and its clinical implications on the treatment of metastatic melanoma. This paper aims to highlight mechanisms of vemurafenib resistance that have been observed so far and offer potential clinical approaches to overcome resistance.
Methods: PubMed, Google Scholar, and EMBASE were searched using the following free text terms: “vemurafenib,” “vemurafenib resistance,” “vemurafenib tyrosine-kinase inhibitor,” “vemurafenib metastatic melanoma,” “vemurafenib alternatives,” and “vemurafenib cancer.” The Cochrane database was searched for randomized controlled trials and systematic reviews using the same search terms above. Two independent reviewers analyzed the search results and corresponding articles.
Discussion: Research over the last decade, most notably in the past two years has revealed a multitude of mechanisms of resistance to vemurafenib. Resistance to therapy with vemurafenib in metastatic melanoma could be explained by the presence of cancer stem cells.
Conclusion: In order to effectively circumvent resistance, it would behoove clinicians to approach metastatic melanoma with a cocktail of inhibitors as opposed to monotherapy.

 
Published: January 1, 2014
 
Senior Editor: Kailyne Van Stavern
 
Junior Editor: Kaitlyn Vitale
 
DOI: Pending
 
Citation:
Dupati A, Gill L. Vemurafenib: Background, Patterns of Resistance, and Strategies to Combat Resistance in Melanoma. Medical Student Research Journal. 2014;3(Winter):36-43.
 
 
References:
1. Lemech C, Infante J, Arkenau HT. The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol. 2012;4(2):61-73. http://dx.doi.org/10.1177/1758834011432949.
 
2. Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012;2(9):791-797.
 
3. Castellani E, Covarelli P, Boselli C, et al. Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World J Surg Oncol. 2012;10:155. http://dx.doi.org/10.1186/1477-7819-10-155.
 
4. De Mello RA. Metastatic melanoma and vemurafenib: novel approaches. Rare Tumors. 2012;4(2):e31. http://dx.doi.org/10.4081/rt.2012.e31.
 
5. Kim J, Lazar AJ, Davies MA, et al. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012;39(9):821-825. http://dx.doi.org/10.1111/j.1600-0560.2012.01950.x.
 
6. Fisher R, Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res. 2012;4:243-252. http://dx.doi.org/10.2147/CMAR.S25284.
 
7. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov. 2011;10(11):811-812. http://dx.doi.org/10.1038/nrd3579.
 
8. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. http://dx.doi.org/10.1186/1479-5876-10-85.
 
9. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972. http://dx.doi.org/10.1038/nature09627.
 
10. Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 2012;18(2):124-131. http://dx.doi.org/10.1097/PPO.0b013e31824b436e.
 
11. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82(3):201-209. http://dx.doi.org/10.1016/j.bcp.2011.05.015.
 
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
 
13. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol. 2012;67(3):488-491. http://dx.doi.org/10.1016/j.jaad.2012.03.022.
 
14. Poulikakos PI, Rosen N. Mutant BRAF melanomas–dependence and resistance. Cancer Cell. 2011;19(1):11-15. http://dx.doi.org/10.1016/j.ccr.2011.01.008.
 
15. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505-509. http://dx.doi.org/10.1038/nature11249.
 
16. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol. 2012;24(2):150-154. http://dx.doi.org/10.1097/CCO.0b013e32834fca92.
 
17. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol. 2011;131(9):1817-1820. http://dx.doi.org/10.1038/jid.2011.147.
 
18. Yadav V, Zhang X, Liu J, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012;287(33):28087-28098. http://dx.doi.org/10.1074/jbc.M112.377218.
 
19. Flaherty KT. Throwing the kitchen sink at melanoma drug development. Pigment Cell Melanoma Res. 2012;25(5):543-544.
 
20. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977. http://dx.doi.org/10.1038/nature09626.
 
21. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol. 2012;132(7):1850-1859. http://dx.doi.org/10.1038/jid.2012.63.
 
22. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene. 2011;30(3):366-371. http://dx.doi.org/10.1038/onc.2010.408.
 
23. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011;71(15):5067-5074. http://dx.doi.org/10.1158/0008-5472.
 
24. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010;3(149):ra84. http://dx.doi.org/10.1126/scisignal.2001148.
 
25. Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 2011;4(166):ra17. http://dx.doi.org/10.1126/scisignal.4170er2.
 
26. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013;19(19):5283-5291. http://dx.doi.org/10.1158/1078-0432.CCR-13-2151.
 
27. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A. 2009;106(48):20411-20416. http://dx.doi.org/10.1073/pnas.0905833106.
 
28. Nissan MH, Solit DB. The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep. 2011;13(6):479-487. http://dx.doi.org/10.1007/s11912-011-0198-4.
 
29. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096. http://dx.doi.org/10.1200/JCO.2010.33.2312.
 
30. Yu L, Favoino E, Wang Y, Ma Y, Deng X, Wang X. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells. Immunol Res. 2011;50(2-3):294-302. http://dx.doi.org/10.1007/s12026-011-8232-z.
 
31. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011;2(4):336-346.
 
32. Jiang CC, Lai F, Thorne RF, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res. 2011;17(4):721-730. http://dx.doi.org/10.1158/1078-0432.CCR-10-2225.
 
33. Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973. http://dx.doi.org/0.1371/journal.pone.0028973.
 
34. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-920. http://dx.doi.org/10.1158/1535-7163.MCT-11-0989.
 
35. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853-4861. http://dx.doi.org/10.1158/0008-5472.CAN-07-6787.
 
36. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750-2760. http://dx.doi.org/10.1158/0008-5472.CAN-10-2954.
 
37. Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget. 2011;2(4):329-335.
 
38. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010;70(16):6670-6681. http://dx.doi.org/10.1158/0008-5472.CAN-09-4471.
 
39. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ. 2012;19(12):2029-2039. http://dx.doi.org/10.1038/cdd.2012.94.
 
40. Paraiso KH, Haarberg HE, Wood E, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012;18(9):2502-2514. http://dx.doi.org/10.1158/1078-0432.CCR-11-2612.
 
41. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7(9):2876-2883. http://dx.doi.org/10.1158/1535-7163.MCT-08-0431.
 
42. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320-5328. http://dx.doi.org/10.1158/1078-0432.CCR-13-0259.
 
43. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695. http://dx.doi.org/10.1016/j.ccr.2010.11.023.
 
44. Su F, Bradley WD, Wang Q, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012;72(4):969-978. http://dx.doi.org/10.1158/0008-5472.CAN-11-1875.
 
45. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene. 2012;31(19):2471-2479. http://dx.doi.org/10.1038/onc.2011.424.
 
46. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-504. http://dx.doi.org/10.1038/nature11183.
 
47. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714. http://dx.doi.org/10.1056/NEJMoa1112302.
 
48. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71(23):7137-7140. http://dx.doi.org/10.1158/0008-5472.CAN-11-1243.
 
49. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26(17):2839-2845. http://dx.doi.org/10.1200/JCO.2007.15.1829.
 
50. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328-9337.
 

The following two tabs change content below.

Kevin Patterson

Executive Editor
Kevin Charles Patterson is a fourth year medical student at Michigan State University’s College of Human Medicine. He is in his eighth year at MSU after graduating with a B.S. in Human Biology and a B.S. in Microbiology, both in 2010. He is considering a career in internal medicine with a combined scientist training program in residency; after residency, his plans include the possibility of a fellowship and the ultimate goal of practicing academic medicine. Editor Note (2013-14): Kevin graduated, matched, and is a resident in Internal Medicine at Ohio State University Wexner Medical Center.